1,996 Shares in Novartis AG (NYSE:NVS) Purchased by Steigerwald Gordon & Koch Inc.

Steigerwald Gordon & Koch Inc. bought a new position in shares of Novartis AG (NYSE:NVSFree Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,996 shares of the company’s stock, valued at approximately $202,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Optimum Investment Advisors grew its position in Novartis by 23.3% during the fourth quarter. Optimum Investment Advisors now owns 530 shares of the company’s stock worth $54,000 after buying an additional 100 shares in the last quarter. Chesley Taft & Associates LLC grew its position in Novartis by 0.3% during the fourth quarter. Chesley Taft & Associates LLC now owns 33,062 shares of the company’s stock worth $3,338,000 after buying an additional 100 shares in the last quarter. Crawford Investment Counsel Inc. grew its position in Novartis by 4.6% during the second quarter. Crawford Investment Counsel Inc. now owns 2,345 shares of the company’s stock worth $237,000 after buying an additional 104 shares in the last quarter. Brady Family Wealth LLC grew its position in Novartis by 3.4% during the third quarter. Brady Family Wealth LLC now owns 3,370 shares of the company’s stock worth $343,000 after buying an additional 110 shares in the last quarter. Finally, 1620 Investment Advisors Inc. grew its position in Novartis by 1.3% during the second quarter. 1620 Investment Advisors Inc. now owns 8,836 shares of the company’s stock worth $892,000 after buying an additional 111 shares in the last quarter. 13.12% of the stock is owned by institutional investors and hedge funds.

Novartis Stock Down 0.5 %

Shares of NVS opened at $95.73 on Tuesday. The company has a market capitalization of $202.91 billion, a P/E ratio of 13.33, a PEG ratio of 1.50 and a beta of 0.54. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.15 and a quick ratio of 0.93. Novartis AG has a one year low of $88.91 and a one year high of $108.78. The business’s 50 day simple moving average is $102.49 and its 200-day simple moving average is $99.85.

Novartis (NYSE:NVSGet Free Report) last announced its earnings results on Tuesday, January 30th. The company reported $1.53 EPS for the quarter, missing the consensus estimate of $1.64 by ($0.11). The business had revenue of $11.42 billion during the quarter, compared to analyst estimates of $11.69 billion. Novartis had a return on equity of 29.90% and a net margin of 29.83%. During the same period in the previous year, the firm earned $1.51 earnings per share. As a group, sell-side analysts predict that Novartis AG will post 7.17 EPS for the current fiscal year.

Novartis Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, March 7th. Investors of record on Friday, March 8th were given a $3.7772 dividend. This represents a yield of 3.1%. The ex-dividend date of this dividend was Thursday, March 7th. This is a boost from Novartis’s previous annual dividend of $3.47. Novartis’s payout ratio is 34.26%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NVS. Morgan Stanley began coverage on Novartis in a report on Tuesday, January 23rd. They set an “equal weight” rating and a $114.00 price objective on the stock. HSBC downgraded Novartis from a “buy” rating to a “hold” rating in a report on Monday, December 18th. StockNews.com began coverage on Novartis in a report on Wednesday, December 6th. They set a “strong-buy” rating on the stock. Finally, BMO Capital Markets began coverage on Novartis in a report on Friday, February 23rd. They set a “market perform” rating and a $114.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Novartis currently has an average rating of “Moderate Buy” and an average target price of $104.33.

Get Our Latest Report on NVS

Novartis Profile

(Free Report)

Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.

Featured Articles

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVSFree Report).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.